Physician profile
Michael B Brumback
NPI 1740235787
$7,647.26
in general payments reported to CMS, 2019-2025
34 companies · $1,932 in 2025
The $1,932 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $325 · 2021: $810 · 2022: $562 · 2023: $1,073 · 2024: $2,040 · 2025: $1,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,867 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,866.76 |
| Education | $178.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $913.46 | 2019-2025 | Farxiga, Fasenra, Lokelma |
| Otsuka America Pharmaceutical, INC. | $763.15 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $517.75 | 2023-2025 | Filspari |
| Calliditas Therapeutics US INC. | $502.44 | 2022-2025 | Tarpeyo |
| Amgen INC. | $463.89 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Opko Pharmaceuticals, LLC | $462.54 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $436.41 | 2021-2025 | |
| Vifor Pharma, INC. | $392.84 | 2019-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $355.95 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $351.02 | 2020-2024 | Terlivaz |
| Glaxosmithkline, LLC. | $242.88 | 2020-2025 | Shingrix, Arexvy |
| Baxter Healthcare | $217.07 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.81 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $202.68 | 2019-2025 | Velphoro, Velphoro |
| Alexion Pharmaceuticals, INC. | $184.23 | 2019-2023 | Ultomiris |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $169.73 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $152.63 | 2021-2025 | Lupkynis |
| Akebia Therapeutics INC | $141.46 | 2025 | Vafseo |
| Ardelyx, INC. | $140.42 | 2023-2024 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $111.14 | 2023-2024 | Oxlumo, Givlaari |
| Mallinckrodt Enterprises LLC | $105.61 | 2019 | |
| Scpharmaceuticals INC. | $97.59 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $90.39 | 2019 | |
| Corcept Therapeutics | $85.97 | 2025 | Korlym |
| Leadiant Biosciences, INC. | $78.14 | 2023 | Carnitor |
| Cormedix INC. | $47.19 | 2024 | Defencath |
| Lilly USA, LLC | $46.24 | 2023-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $40.57 | 2020-2022 | |
| Genzyme Corporation | $27.52 | 2024 | |
| Novo Nordisk INC | $26.66 | 2025 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $22.69 | 2019 | |
| Janssen Scientific Affairs, LLC | $18.92 | 2019 | |
| Bard Peripheral Vascular, INC. | $16.79 | 2023 | |
| Shire North American Group INC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brumback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.